Literature DB >> 16239433

Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

Naoto Hirano1, Marcus O Butler, Zhinan Xia, Sascha Ansén, Michael S von Bergwelt-Baildon, Donna Neuberg, Gordon J Freeman, Lee M Nadler.   

Abstract

Following T-cell receptor and CD28 signaling, CD8+ T cells express a receptor for CD83, a molecule up-regulated on functionally mature dendritic cells. Although this expression pattern suggests that CD83 is involved in adaptive immunity, little is known about its function in the periphery, and the existence of its ligand on T cells is controversial. We demonstrate that the engagement of the CD83 ligand (CD83L) preferentially enriches and significantly amplifies the number of antigen-specific CD8+ T cells. Coengagement of the T-cell receptor, CD28, and CD83L supports priming of naive CD8+ T cells that retain antigen specificity and cytotoxic function for more than 6 months. Therefore, engagement of the CD83L provides a unique signal to activated CD8+ T cells that could be exploited to generate long-lived antigen-specific cytotoxic T cells for the treatment of cancer and infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239433      PMCID: PMC1895397          DOI: 10.1182/blood-2005-05-2073

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies.

Authors:  James Arthos; Claudia Cicala; Tavis D Steenbeke; Tae-Wook Chun; Charles Dela Cruz; Douglas B Hanback; Prateeti Khazanie; Daniel Nam; Peter Schuck; Sara M Selig; Donald Van Ryk; Margery A Chaikin; Anthony S Fauci
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

2.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Authors:  Mathias Oelke; Marcela V Maus; Dominic Didiano; Carl H June; Andreas Mackensen; Jonathan P Schneck
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

3.  Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells.

Authors:  A L Zarling; J G Johnson; R W Hoffman; D R Lee
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

Review 4.  CD28-mediated co-stimulation: a quantitative support for TCR signalling.

Authors:  Oreste Acuto; Frédérique Michel
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

5.  Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.

Authors:  Uluhan Sili; M Helen Huls; Alan R Davis; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunother       Date:  2003 May-Jun       Impact factor: 4.456

Review 6.  The ABCs of artificial antigen presentation.

Authors:  Jiyun V Kim; Jean-Baptiste Latouche; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2004-04       Impact factor: 54.908

7.  Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.

Authors:  Michael S von Bergwelt-Baildon; Robert H Vonderheide; Britta Maecker; Naoto Hirano; Karen S Anderson; Marcus O Butler; Zhinan Xia; Wan Y Zeng; Kai W Wucherpfennig; Lee M Nadler; Joachim L Schultze
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 8.  Some interfaces of dendritic cell biology.

Authors:  Ralph M Steinman
Journal:  APMIS       Date:  2003 Jul-Aug       Impact factor: 3.205

9.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

Authors:  Alfred Zippelius; Pascal Batard; Verena Rubio-Godoy; Gilles Bioley; Danielle Liénard; Ferdy Lejeune; Donata Rimoldi; Philippe Guillaume; Norbert Meidenbauer; Andreas Mackensen; Nathalie Rufer; Norbert Lubenow; Daniel Speiser; Jean-Charles Cerottini; Pedro Romero; Mikaël J Pittet
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

10.  Autoantibodies frequently detected in patients with aplastic anemia.

Authors:  Naoto Hirano; Marcus O Butler; Michael S Von Bergwelt-Baildon; Britta Maecker; Joachim L Schultze; Kevin C O'Connor; Peter H Schur; Seiji Kojima; Eva C Guinan; Lee M Nadler
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

View more
  65 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 2.  T cell engineering as therapy for cancer and HIV: our synthetic future.

Authors:  Carl H June; Bruce L Levine
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

Review 3.  Dendritic cell CD83: a therapeutic target or innocent bystander?

Authors:  Charlene M Prazma; Thomas F Tedder
Journal:  Immunol Lett       Date:  2007-10-29       Impact factor: 3.685

Review 4.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 5.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.

Authors:  Shirin Munir; Cyril Le Nouen; Cindy Luongo; Ursula J Buchholz; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.

Authors:  Sascha Ansén; Marcus O Butler; Alla Berezovskaya; Andrew P Murray; Kristen Stevenson; Lee M Nadler; Naoto Hirano
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Therapeutic vaccines for malignant brain tumors.

Authors:  Michael P Gustafson; Keith L Knutson; Allan B Dietz
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.